Go Pro
NASDAQ:SWKH

SWK Q4 2025 Earnings Report

SWK EPS Results

Actual EPS
-$1.59
Consensus EPS
$0.52
Beat/Miss
Missed by -$2.11
One Year Ago EPS
N/A

SWK Revenue Results

Actual Revenue
$8.69 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

SWK Announcement Details

Quarter
Q4 2025
Time
Before Market Opens
Conference Call Date
Thursday, March 26, 2026
Conference Call Time
10:00AM ET

Earnings Documents

SWK Earnings Headlines

Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery.tc pixel
UBS Releases a Buy Rating on Stanley Black & Decker (SWK)
See More SWK Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like SWK? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SWK and other key companies, straight to your email.

About SWK

SWK (NASDAQ:SWKH) Holdings Corporation, offers specialty finance and asset management services in the United States. It operates in two segments, Finance Receivables and Pharmaceutical Development. The Finance Receivables segment provides customized financing solutions to a range of life science companies, including companies in the biotechnology, medical device, medical diagnostics and related tools, animal health, and pharmaceutical industries, as well as institutions and inventors. This segment also offers non-discretionary investment advisory services to institutional clients in separately managed accounts to invest in life science finance. The Pharmaceutical Development segment provides customers pharmaceutical development, formulation, and manufacturing services, as well as formulation solutions built around its proprietary oral drug delivery technologies, the Peptelligence platform. It also offers intellectual property licensing business. The company was formerly known as Kana Software, Inc. and changed its name to SWK Holdings Corporation in December 2009. SWK Holdings Corporation was incorporated in 1996 and is headquartered in Dallas, Texas.

View SWK Profile